Professional Documents
Culture Documents
To cite this article: Stelios F. Assimakopoulos, Diamanto Aretha, Dimitris Komninos, Dimitra
Dimitropoulou, Maria Lagadinou, Lydia Leonidou, Ioanna Oikonomou, Athanasia Mouzaki & Markos
Marangos (2021) N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in
patients with COVID-19 pneumonia: a two-center retrospective cohort study, Infectious Diseases,
53:11, 847-854, DOI: 10.1080/23744235.2021.1945675
ORIGINAL ARTICLE
ABSTRACT
Background: N-acetyl-cysteine (NAC) has been previously shown to exert beneficial effects in diverse respiratory diseases,
through antioxidant and anti-inflammatory actions. Our aim was to evaluate NAC potential impact in hospitalised patients
with COVID-19 pneumonia, in terms of progression to severe respiratory failure (SRF) and mortality.
Patients and Methods: This retrospective, two-centre cohort study included consecutive patients hospitalised with moder-
ate or severe COVID-19 pneumonia. Patients who received standard of care were compared with patients who additionally
received NAC 600 mg bid orally for 14 days. Patients’ clinical course was recorded regarding (i) the development of SRF
(PO2/FiO2 <150) requiring mechanical ventilation support and (ii) mortality at 14 and 28 days.
Results: A total of 82 patients were included, 42 in the NAC group and 40 in the control group. Treatment with oral NAC
led to significantly lower rates of progression to SRF as compared to the control group (p < .01). Patients in the NAC group
presented significantly lower 14- and 28-day mortality as compared to controls (p < .001 and p < .01 respectively). NAC
treatment significantly reduced 14- and 28-day mortality in patients with severe disease (p < .001, respectively). NAC
improved over time the PO2/FiO2 ratio and decreased the white blood cell, CRP, D-dimers and LDH levels. In the multivari-
able logistic regression analysis, non-severe illness and NAC administration were independent predictors of 28-
days survival.
Conclusion: Oral NAC administration (1200 mg/d) in patients with COVID-19 pneumonia reduces the risk for mechanical
ventilation and mortality. Our findings need to be confirmed by properly designed prospective clinical trials.
exacerbations and exerts antioxidant and anti-inflamma- significance for multiple comparisons was adjusted with
tory actions in community-acquired pneumonia [4,5]. Dunn’s test. The chi-squared test was used to compare
There is also extensive clinical experience in diverse clin- the proportional and categorical data. Uni-and multivari-
ical entities, showing the high tolerability and safety of able logistic regression was used to identify predictors
this drug, even at much higher doses and for longer of mortality at 28 days. Variables with p-values <.02 in
periods of administration than the commonly prescribed the univariate regression were included in the multivari-
dose of 600 mg/d as a mucolytic agent [6]. able model while the choice of variables was also based
on scientific knowledge and considered potential collin-
Outcome measures earity. Multicollinearity issues were tested using the vari-
ance inflation factor (VIF). The possibility of survival and
Two major clinical end-points of patients’ clinical course
non-development of severe respiratory failure at 28 days
were recorded: (a) development of severe respiratory
were also assessed with survival analysis (Kaplan-Meier
failure (SRF) (defined as PO2/FiO2 <150) requiring inva-
curves). In all cases, p-values <.05 were considered
sive or non-invasive mechanical ventilation, within
significant.
14 days from hospital admission (patients with SRF
underwent computed tomographic pulmonary angiog-
raphy for exclusion of thromboembolic disease) and (b) Results
mortality at 14 and 28 days. Patients’ baseline characteristics
A total of 82 patients were included in the study: 42 in
Statistical analysis the NAC (treatment) group and 40 in the control group.
Data were analysed using the SPSS statistical package The baseline characteristics of the patients including
for Windows (version 25.0; IBM, Armonk, USA) and the age, gender, and Charlson co-morbidity index were simi-
GraphPad Prism Software (La Jolla, CA, version 9.1.0.). lar between groups (p < .05) (Table 1). Significantly more
Normality of data was tested using the Shapiro-Wilk patients in the NAC group presented with severe disease
test. All parameters exhibited non-normal distribution (p ¼ .004).
except leucocytes, fibrinogen and PLT. Normally distrib-
uted data that measured at different time points were
Differences in patients’ clinico-laboratory parameters
compared, between and within groups, using repeated
over time
analysis of variance (ANOVA Repeated Measures-General
Linear Model) followed by post-hoc Student’s t-test while Cohort differences in patients’ clinico-laboratory parame-
Bonferroni correction was used to adjust the level of sig- ters measured at different time points are presented in
nificance for multiple comparisons. Similarly, for non- Figure 1. There were no statistically significant differen-
normally distributed data, the nonparametric analysis of ces between the two study groups at baseline (day 1),
variance (Kruskal-Wallis test) followed by a post-hoc while at day 7 and 14 there were statistically significant
Mann-Whitney U-test was used and the level of differences for PO2/FiO2, WBCs, CRP, D-dimers and LDH.
Table 1. Patients’ clinico-laboratory baseline characteristics in the control and the NAC study groups.
Group
Pts Characteristics NAC Control p-value
Number 42 40
Gender (male/Female) 28/14 27/13 .93
Age (years) 61 (16) 64 (17) .3
Charlson co-morbidity Index 2 (4–1) 3 (5–2) .09
Severe illness (pt no, %) 26 (68.4) 12 (31.6) .004
PO2/FiO2 ratio 297 (339–247) 271 (372–188) .37
WBCs (absolute number/mm3) 5.665 (7.185–3.898) 6.120 (8.640–4.925) .15
Lymphocytes (absolute number/mm3) 1.017 (702) 1.270 (1.253) .26
CRP (mg/dl) 4 (7–2) 7 (13–3) .07
Ferritin (ng/ml) 515 (1200–298) 767.5 (1388–396) .46
D-dimers (lg/l) 630 (1205–455) 1.150 (1665–492) .13
Fibrinogen (mg/dl) 496 (140) 554 (160) .18
LDH (U/l) 256 (319–222) 314 (423–221) .11
PLT (x103/ll) 214 (459) 208 (911) .70
Continuous data are presented as mean (SD) or median (interquartile range). NAC: N-acetylcysteine, SRF: severe respiratory failure; WBC: white
blood cells. P-values <.05 were considered significant.
850 S. F. ASSIMAKOPOULOS ET AL.
Figure 1. Cohort differences in patients’ characteristics measured at different time points. WBCs: white blood cells, CRP: C-reactive protein;
SRF: severe respiratory failure.
Figure 3. Mortality at 14- and 28-days after admission in the control and the NAC study groups (A). Mortality differences between groups
according to baseline disease severity (moderate vs. severe) (B). NAC: N-acetylcysteine, no: number.
4.4-1436) were independent predictors of 28- death rates for age-comparable hospitalised patients
days mortality. with COVID-19 pneumonia have been previously
reported [7,8]. Amongst the 12 deceased patients in the
Discussion control group, 4 had multiple comorbidities with a
Charlson co-morbidity index 7 and 7 patients were
The present study showed that orally administered NAC 75 years old. Moreover 8/12 patients progressed to
at a dose of 1200 mg per day in hospitalised patients severe respiratory failure and required invasive mechan-
with moderate or severe COVID-19 pneumonia, prevents ical ventilation, which is associated with increased mor-
their clinical deterioration to severe respiratory failure tality [9]. It is noteworthy that the NAC group included
requiring invasive or non-invasive mechanical ventilation significantly more patients in severe condition as com-
and reduces 14- and 28-day mortality. Advanced age, pared to the standard of care group, although there was
multiple comorbidities, low lymphocyte count, disease no significant difference in baseline PO2/FiO2 values
severity and standard of care treatment were identified between the two study groups. This might be explained
as significant factors associated with mortality in univari- by the fact that PO2/FiO2 ratio was not the only deter-
ate regression analysis. In multivariate regression ana- minant of severe disease according to the severity classi-
lysis, only severe disease and standard of care treatment fication criteria used in the present study [3], while its
(without NAC) were associated with increased mortality. range in severe patients was wide (150 299 mmHg).
In the control group, with a mean age of 64 years, a NAC survival benefit was mainly attributed to signifi-
high 28-day mortality rate of 30% was recorded. Similar cantly reduced mortality in patients with severe COVID-
852 S. F. ASSIMAKOPOULOS ET AL.
19 pneumonia (2/42 in NAC vs 8/40 in standard of care). administration improved oxygenation over time, and
Regarding patients with moderate disease at admission reduced leukocytes, CRP and d-dimers levels, which is
0/16 died in the NAC group, while in the control group suggestive of its anti-inflammatory action. The finding of
3/28 patients died within the first 14 days and one add- absence of ferritin reduction at 7 and 14 days after NAC
itional patient died within 28 days; however this trend treatment initiation might be potentially explained by a
for mortality reduction by NAC did not reach statistical slowest kinetic alteration of ferritin as compared to
significance owing to small number of moderately ill other inflammatory indices. Previous studies in sepsis
patients. According to the presented results NAC have demonstrated that although CRP and ferritin were
elevated analogously, their drop after treatment was not
paralleled and ferritin declined more slowly than CRP
possibly because of its longer half-life time [10].
Previous studies have demonstrated that NAC exerts
beneficial actions in diverse respiratory diseases. NAC
administration at a daily dose of 1200 mg has been
shown to prevent exacerbations of chronic obstructive
pulmonary disease [5]. A recent study including patients
with community-acquired pneumonia, showed that the
addition of 1200 mg/d of NAC to conventional treatment
reduced oxidative stress and the inflammatory response
[4]. Nasogastric administration of 1200 mg/d NAC has
been shown to prevent the development of ventilator-
associated pneumonia in intubated patients and leading
to shorter duration of hospital and intensive care unit
(ICU) stay [11].
The potential mechanisms of NAC beneficial actions
have been investigated in several in vitro and in vivo
studies. Beyond its well established action as a precursor
of glutathione, diverse additional mechanisms have
been described for its antioxidant and anti-inflammatory
actions; (i) NAC downregulates the mRNA expression of
the inflammasome NLRP3 thus decreasing the proinflam-
matory cytokine expression and release from activated
mononuclear phagocytes [12], (ii) inhibits the endotoxin-
Figure 4. Kaplan-Meier curves for 28 days survival (A) and mechan-
induced release of IL-1b, IL-8, and TNF-a [13], (iii)
ical ventilation free survival (B), for the control and NAC study improves gut barrier dysfunction thus preventing sys-
groups. NAC: N-acetylcysteine temic endotoxemia and inflammatory response, while
Table 2. Predictors of mortality at 28 days based on an uni- and multi-variable logistic regression model.
Death at 28 days Univariate regression Multivariate regression
Variable Yes No OR (95% CI) p Value aOR (95% CI) p Value
Age (mean, SD) 77.5 (10) 59 (15) 1.17 (1.05–1.2) <.001 1.1 (0.98–1.3) .13
Gender (male/female) 8/6 47/21 1.6 (0.5–5.4) .38
Charlson Index (median, IQR) 4 (3.75–6.25) 2 (4–1) 2 (1.4–3.1) <.001 1.4 (0.7–3.3) .32
Severity of illness (severe, pts no) 10 28 3.5 (1.1–14) <.001 15.3 (1.5–335) .04
Group (NAC/control) 2/12 40/28 8.5 (2.1–57.8) .007 48 (4.4–1436) .006
Baseline measurements
PO2/FiO2 ratio (median/IQR) 239 (302–159) 303 (348–230) 0.99 (0.98–1) .16
WBCs (absolute number/mm3, median/IQR) 7400 (9890–5290) 5840 (7295–4070) 1 (0.9–1) .53
Lymphocytes (absolute number/mm3, mean/SD) 825 (366) 1202 (1079) 0.99 (0.99–0.991) .01 0.99 (0.99–0.99) .05
CRP (mg/dl, median/IQR) 7.5 (13–3.5) 4.4 (8.6–2.2) 1 (0.9–1.1) .2
Ferritin (ng/ml, median/IQR) 771 (1811–418) 614 (1273–299) 1 (0.9–1) .37
D-dimers (lg/l, median/IQR) 1160 (2400–540) 645 (1285–423) 1 (1–1) .19
LDH (U/l, median/IQR) 382 (667–245) 287 (375–239) 1.01 (1.01–1.01) .02
OR: Odds-Ratio; 95%CI: 95% Confidence interval; aOR: adjusted Odds-Ratio; WBCs: white blood cells; CRP: C-reactive protein; IQR: Interquartile range.
Factors that were included in the multivariate regression. p-values <.05 in multivariate logistic regression are considered significant.
INFECTIOUS DISEASES 853
previous studies have shown that COVID-19 has been of thiols with reactive radicals can generate thiyl radi-
associated with gut barrier dysfunction and systemic cals, depending on the baseline levels of oxidative stress
endotoxemia [14,15] (iii) downregulates programmed [24]. Previous in vitro and experimental animal studies
cell death protein 1 expression in CD4þ and CD8þ lym- have shown that higher doses of NAC may exert a
phocytes thus increasing their longevity and counts [16]. prooxidant action, depending on the nature of the radi-
Additionally, NAC may exert a direct antiviral action cals generated by the biological system [24–26].
against SARS-CoV-2. A previous in vitro study has dem- Specifically, high NAC doses have been shown to
onstrated that NAC inhibits the replication of other enhance the Fe2þ/H2O2-dependent oxidative stress and
respiratory viruses like influenza A and B and respiratory increase superoxide radical formation [24,25].
syncytial virus in human pulmonary epithelial cells [17]. Some limitations of the current study should be
Replication of RNA viruses, including human coronavi- acknowledged. First, the presented study is retrospective
ruses, in epithelial cells requires an active NF-jB path- with a limited number of patients. Second, patients
way. NAC has been demonstrated to inhibit NF-jB thus were not matched for disease severity, although this did
exhibiting the theoretical potential to inhibit SARS-CoV-2 not affect the NAC positive impact in COVID-19-related
replication [18]. pneumonia because patients who received NAC had a
Despite the pathophysiological rationale for the higher severity disease. Third, even though the basis of
potential value of NAC in COVID-19, there is very limited NAC use in COVID-19 was its antioxidant action, this fac-
data regarding its clinical impact in this disease. To the tor was not investigated by appropriate indices meas-
best of our knowledge, there is only one double-blind, urements. Therefore, the mechanisms of the observed
placebo-controlled randomised unicentric trial, con- clinical results could only be discussed on a theoret-
ducted in Brazil, where 135 patients diagnosed with ical basis.
severe COVID-19 beyond standard of care were assigned In conclusion, the present study provides evidence
1:1 to either 21 g of IV NAC (14 g in the first 4 h and 7 g that 1200 mg/d of oral NAC administration in patients
in the next 16 h) or placebo [19]. This study found no with COVID-19 pneumonia prevents development of
difference regarding the progression to severe respira- severe respiratory failure and improves survival. Our
tory failure requiring invasive or non-invasive mechanical findings need to be confirmed by properly designed
ventilation, admission to ICU and mortality. However, in prospective clinical trials. In addition, the optimal time
accordance with our positive results, previous case for NAC treatment initiation (e.g. early after symptoms
reports and series of patients with COVID-19 have onset or later in the disease course) remains to be eluci-
shown that NAC administered at 1200 mg/d induced a dated. Until then, considering the excellent safety profile
positive clinical impact [20,21]. A potential explanation and low cost of oral NAC, its use as adjunctive therapy
for these contradictory results might have been the in COVID-19 might be of reasonable value.
short treatment duration with NAC (20 h) in the Brazilian
study, as compared to its repeated daily administration
Disclosure statement
for 14 days in the present study. It has been previously
shown that early NAC discontinuation in COVID-19 was The authors declare that they have no conflict of interest.
associated with relapse of laboratory indices of inflam-
mation [21]. An additional explanation might have been ORCID
the significantly different doses of NAC used in the pre-
Stelios F. Assimakopoulos http://orcid.org/0000-0002-
sent and the Brazilian study (1.2 vs. 21 g). Very higher 6901-3681
doses of intravenous NAC (200 mg/kg/d) have been
used clinically for the treatment of ARDS and a meta-
References
analysis of randomised clinical trials on this field failed
to demonstrate a survival benefit by high NAC dose [1] Mehta P, McAuley DF, Brown M, et al.; HLH Across
administration, although length of ICU stay was Speciality Collaboration, UK. COVID-19: consider cytokine
storm syndromes and immunosuppression. Lancet. 2020;
decreased [22]. It should not be neglected that it has
395(10229):1033–1034.
been previously shown that high doses of other free
[2] Conner EM, Grisham MB. Inflammation, free radicals, and
radical scavengers like beta-carotene, vitamin E, and antioxidants. Nutrition. 1996;12(4):274–277.
vitamin C have led to enhanced oxidative stress [23]. [3] COVID-19 Treatment Guidelines Panel. Coronavirus Disease
Regarding thiol containing compounds, the interaction 2019 (COVID-19) Treatment Guidelines. National Institutes
854 S. F. ASSIMAKOPOULOS ET AL.
of Health. Available from: https://www.covid19treatment- [16] Scheffel MJ, Scurti G, Wyatt MM, et al. N-acetyl cysteine
guidelines.nih.gov/ protects anti-melanoma cytotoxic T cells from exhaustion
[4] Zhang Q, Ju Y, Ma Y, et al. N-acetylcysteine improves oxi- induced by rapid expansion via the downmodulation of
dative stress and inflammatory response in patients with Foxo1 in an Akt-dependent manner. Cancer Immunol
community acquired pneumonia: a randomized controlled Immunother. 2018;67(4):691–702.
trial. Medicine (Baltimore). 2018;97(45):e13087. [17] Mata M, Morcillo E, Gimeno C, et al. N-acetyl-L-cysteine
[5] Sanguinetti CM. N-acetylcysteine in COPD: why, how, and (NAC) inhibit mucin synthesis and pro-inflammatory media-
when? Multidiscip Respir Med. 2015;11:8.
tors in alveolar type II epithelial cells infected with influ-
[6] Millea PJ. N-acetylcysteine: multiple clinical applications.
enza virus A and B and with respiratory syncytial virus
Am Fam Physician. 2009;80(3):265–269.
(RSV). Biochem Pharmacol. 2011;82(5):548–555.
[7] Selcuk M, Cinar T, Keskin M, et al. Is the use of ACE inb/
[18] Shi Z, Puyo CA. N-acetylcysteine to combat COVID-19: an
ARBs associated with higher in-hospital mortality in Covid-
evidence review. Ther Clin Risk Manag. 2020;16:1047–1055.
19 pneumonia patients? Clin Exp Hypertens. 2020;42(8):
[19] de Alencar JCG, Moreira CL, Muller AD, et al. Double-blind,
738–742.
[8] Wang Z, Wang Z. Identification of risk factors for in-hospital randomized, placebo-controlled trial with N-acetylcysteine
death of COVID-19 pneumonia - lessions from the early for treatment of severe acute respiratory syndrome caused
outbreak. BMC Infect Dis. 2021;21(1):113. by COVID-19. Clin Infect Dis. 2020;72(11):e736–e741.
[9] de Souza FSH, Hojo-Souza NS, Batista B. D d O, et al. On [20] Horowitz RI, Freeman PR, Bruzzese J. Efficacy of glutathione
the analysis of mortality risk factors for hospitalized COVID- therapy in relieving dyspnea associated with COVID-19
19 patients: A data-driven study using the major Brazilian pneumonia: A report of 2 cases. Respir Med Case Rep.
database. PLoS One. 2021;16(3):e0248580. 2020;30:101063.
[10] Northrop-Clewes CA. Interpreting indicators of iron status [21] Ibrahim H, Perl A, Smith D, et al. Therapeutic blockade of
during an acute phase response-lessons from malaria and inflammation in severe COVID-19 infection with intraven-
human immunodeficiency virus. Ann Clin Biochem. 2008; ous N-acetylcysteine. Clin Immunol. 2020;219:108544.
45(Pt 1):18–32. [22] Zhang Y, Ding S, Li C, et al. Effects of N-acetylcysteine
[11] Sharafkhah M, Abdolrazaghnejad A, Zarinfar N, et al. Safety treatment in acute respiratory distress syndrome: A meta-
and efficacy of N-acetyl-cysteine for prophylaxis of ventila- analysis. Exp Ther Med. 2017;14(4):2863–2868.
tor-associated pneumonia: a randomized, double blind, pla- [23] Sotler R, Poljsak B, Dahmane R, et al. Prooxidant Activities
cebo-controlled clinical trial. Med Gas Res. 2018;8(1):19–23. of Antioxidants and Their Impact on Health. Acta Clin
[12] Liu Y, Yao W, Xu J, et al. The anti-inflammatory effects of Croat. 2019;58(4):726–736.
acetaminophen and N-acetylcysteine through suppression [24] Sagrista ML, Garcia AE, Africa De Madariaga M, et al.
of the NLRP3 inflammasome pathway in LPS-challenged
Antioxidant and pro-oxidant effect of the thiolic com-
piglet mononuclear phagocytes. Innate Immun. 2015;21(6):
pounds N-acetyl-L-cysteine and glutathione against free
587–597.
radical-induced lipid peroxidation. Free Radic Res. 2002;
[13] Lee SI, Kang KS. N-acetylcysteine modulates lipopolysac-
36(3):329–340.
charide-induced intestinal dysfunction. Sci Rep. 2019;9(1):
[25] Harvey BH, Joubert C, Du Preez JL, et al. Effect of chronic
1004.
[14] Assimakopoulos SF, Maroulis I, Patsoukis N, et al. Effect of N-acetyl cysteine administration on oxidative status in the
antioxidant treatments on the gut-liver axis oxidative status presence and absence of induced oxidative stress in rat
and function in bile duct-ligated rats. World J Surg. 2007; striatum. Neurochem Res. 2008;33(3):508–517.
31(10):2023–2032. [26] Takahashi N, Yoshida T, Ohnuma A, et al. The enhancing
[15] Sirivongrangson P, Kulvichit W, Payungporn S, et al. effect of the antioxidant N-acetylcysteine on urinary blad-
Endotoxemia and circulating bacteriome in severe COVID- der injury induced by dimethylarsinic acid. Toxicol Pathol.
19 patients. Intensive Care Med Exp. 2020;8(1):72. 2011;39(7):1107–1114.